Loading…
Reported covered position: Senate HELP: Senior Health Policy Advisor-Ranking Member (RM); Senior Policy Advisor-Chair; Health Policy Advisor-Chair; Prof Staff Member-Chair; Prof Staff Member-RM; Prof Staff Member RM-Senate Budget; Leg Corres-Senate; Staff Assistant-Senate
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Source: Senate LDA
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act of 2025
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Accelerating Kids’ Access to Care Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: LEAVITT PARTNERS, LLC
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2026 · third_quarter · Q3
Pharmaceutical, medical products, and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2026 · second_quarter · Q2
Pharmaceutical, medical products, and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2026 · first_quarter · Q1
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPRING CARE, INC. via LEAVITT PARTNERS, LLC
2026 · first_quarter · RR
- Behavioral health care and technology related issues. - SAFE BOTS Act
- Behavioral health care and technology related issues. - SAFE BOTS Act
- Behavioral health care and technology related issues. - SAFE BOTS Act
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · fourth_quarter · Q4
Work with Congress and the Administration to ensure Medicaid coverage of genomic sequencing for children with suspected rare diseases, genetic disorders, and undiagnosed conditions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2025 · third_quarter · Q3
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2025 · second_quarter · RA
Newborn screening and pharmaceuticals.
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2025 · second_quarter · Q2
Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via LEAVITT PARTNERS, LLC
2025 · second_quarter · RR
Newborn screening and pharmaceuticals.
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2025 · first_quarter · Q1
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2024 · fourth_quarter · Q4
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · third_quarter · 3A
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · second_quarter · 2A
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2024 · third_quarter · Q3
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA) via LEAVITT PARTNERS, LLC
2024 · second_quarter · RR
Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.
BAXTER HEALTHCARE via LEAVITT PARTNERS, LLC
2024 · second_quarter · Q2
Pharmaceutical and patient safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE